Efficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin

The Swedish Enuresis Trial (SWEET) was conducted to evaluate the long-term safety and efficacy of intranasal desmopressin treatment in children with p rimary, monosymptomatic nocturnal enuresis (PMNE). The study had an open, m ulticentre design and comprised a 4-wk observation period, a 6-wk dose titr ation period (with 20-40 mu g desmopressin) and a 1-y, long-term treatment period. A treatment-free week was introduced every 3 mo to identify dry pat ients. In total, 399 children aged 6-12 y with PMNE were recruited. Of thes e, 245 patients (61%) experienced greater than or equal to 50% reduction in the number of wet nights during the last 4-wk of dose titration compared w ith the observation period. These responders entered the long-term phase of the trial. The mean number of wet nights per week decreased from a median of 5.3 (range 1.3-7.0) during: the observation period to a median of 0.8 (r ange 0.0-5.0) during the last 3-mo period. Seventy-seven children became dr y, 63 (83%) within 6 mo of treatment initiation. The percentage of children who became dry was similar in all age groups. Significantly fewer children in the lowest age group were defined as responders (52%; 95% CI 45, 59) am ong the 6-7-y-olds compared to 65% (56, 74) and 81% (72, 90) in the two old er age groups. Desmopressin was well tolerated. No serious drug-related adv erse events were recorded and no clinical symptoms of hyponatraemia were re ported. The SWEET trial has demonstrated that desmopressin is both safe and effective for the long-term treatment of PMNE, with a significant therapeu tic effect also in children of 6-7 y of age.